Skip to main content
. Author manuscript; available in PMC: 2022 May 14.
Published in final edited form as: Circ Res. 2021 May 13;128(10):1435–1450. doi: 10.1161/CIRCRESAHA.121.318158

Figure 4. Potential Direct Myocardial and Indirect ± Systemic Effects of SGLT2 inhibitors.

Figure 4.

(Key: CAMKII = calmodulin-dependent protein kinase II; EPO = erythropoietin; NHE = sodium/hydrogen exchanger; NLRP3 = nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3; SGLT2i = sodium glucose co-transporter 1(2) inhibitor; SNS = sympathetic nervous system. (Reproduced from Lopaschuk GD and Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5:632–644).